Cargando…
Remdesivir in Solid Organ Recipients for COVID-19 Pneumonia
Solid organ transplant (SOT) recipients represent a vulnerable patient population and are of high risk for airborne viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Treatment of COVID-19 is still challenging, as no proven therapeutic regimen is available for i...
Autores principales: | Fesu, Dorottya, Bohacs, Aniko, Hidvegi, Edit, Matics, Zsombor, Polivka, Lorinc, Horvath, Peter, Czaller, Ibolya, Sutto, Zoltan, Eszes, Noemi, Vincze, Krisztina, Muller, Veronika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626440/ https://www.ncbi.nlm.nih.gov/pubmed/36400587 http://dx.doi.org/10.1016/j.transproceed.2022.10.043 |
Ejemplares similares
-
Post-COVID interstitial lung disease in symptomatic patients after COVID-19 disease
por: Fesu, Dorottya, et al.
Publicado: (2023) -
Serum Progranulin Level Might Differentiate Non-IPF ILD from IPF
por: Tóth, Nóra Melinda, et al.
Publicado: (2023) -
Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment
por: Polivka, Lorinc, et al.
Publicado: (2022) -
Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox
por: Nagy, Alexandra, et al.
Publicado: (2022) -
Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry
por: Nagy, Tamas, et al.
Publicado: (2022)